GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (2)
  • Ichikawa, Hiroshi  (2)
Material
Publisher
  • Wiley  (2)
Language
Years
Subjects(RVK)
  • 1
    In: Cancer Science, Wiley, Vol. 110, No. 1 ( 2019-01), p. 6-15
    Abstract: Next generation sequencing (NGS) has been an invaluable tool to put genomic sequencing into clinical practice. The incorporation of clinically relevant target sequences into NGS‐based gene panel tests has generated practical diagnostic tools that enable individualized cancer‐patient care. The clinical utility of gene panel testing includes investigation of the genetic basis for an individual's response to therapy, such as signaling pathways associated with a response to specific therapies, microsatellite instability and a hypermutated phenotype, and deficiency in the DNA double‐strand break repair pathway. In this review, we describe the concept of precision cancer medicine using target sequences in gene panel tests as well as the importance of the control of sample quality in routine NGS‐based genomic testing. We describe geographic and ethnic differences in cancer genomes, and discuss issues that need to be addressed in the future based on our experiences in Japan.
    Type of Medium: Online Resource
    ISSN: 1347-9032 , 1349-7006
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2115647-5
    detail.hit.zdb_id: 2111204-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Histopathology, Wiley, Vol. 74, No. 6 ( 2019-05), p. 873-882
    Abstract: SMAD 4 acts as a tumour suppressor, and the loss of SMAD 4 is associated with poor prognosis in colorectal cancer ( CRC ) patients. Although next‐generation sequencing ( NGS ) enabled us to detect numerous genetic alterations in a single assay, the clinical significance of SMAD 4 alteration detected with NGS has not been fully investigated. The aim of this study was to evaluate the clinicopathological characteristics and clinical significance of SMAD 4 alteration detected with NGS in CRC . Methods and results We retrospectively investigated 201 patients with stage I– IV CRC , by using a 415‐gene panel. To analyse the relationship between SMAD 4 alteration and other clinicopathological characteristics, we evaluated clinicopathological variables, including invasive‐front pathological markers: tumour budding, poorly differentiated cluster, and Crohn‐like lymphoid reaction. Fifty‐six patients (28%) had SMAD 4 alteration: 24 and 32 patients had SMAD 4 mutation and deletion, respectively. SMAD 4 alteration was significantly associated with T category ( P  = 0.027), N category ( P  = 0.037), M category ( P  = 0.028), and invasive‐front pathological markers, such as poorly differentiated cluster grade 3 ( P  = 0.020) and absence of Crohn‐like lymphoid reaction ( P  = 0.004). Immunohistochemistry revealed that SMAD 4 alteration was significantly associated with loss of SMAD 4 ( P  = 0.023). In 90 patients with stage I– III disease, SMAD 4 alteration was significantly associated with poor prognosis for relapse‐free and overall survival ( P  = 0.047; P  = 0.022, respectively). Conversely, in 111 patients with stage IV disease, SMAD 4 alteration was not significantly associated with overall survival. Conclusion SMAD 4 alteration is associated with invasive‐front pathological markers and poor prognosis in stage I– III CRC patients.
    Type of Medium: Online Resource
    ISSN: 0309-0167 , 1365-2559
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2006447-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...